Aclaris Therapeutics to Attend Upcoming Investor Conference

WAYNE, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that management will attend the following conference:

• Management will host investor meetings during the William Blair & Company 3rd Annual Late-Stage Therapeutics Conference in New York, NY from Thursday, April 4, 2019. 

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of people with dermatological and immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes two FDA-approved medicines, one late-stage investigational medicine, and a pipeline powered by a robust R&D engine exploring protein kinase regulation. Aclaris Therapeutics’ active development programs focus on areas where significant treatment gaps exist, such as common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx. 

Contact:

Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate Strategy/Investor Relations484-329-2140[email protected] 

Media ContactSheila KennedyVice President, Corporate Communications484-321-5559[email protected] 

Source: Aclaris Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Wells Fargo invests $1.5 million with Habitat for Humanity to scale innovative home construction in rural communities
• Peripheral Raises $8.7M co-led by Inovia Capital and Deloitte Ventures, to Expand Spatial Intelligence Platform for Live Sports